Show simple item record

dc.contributor.authorHeaney, Robert P.en_US
dc.contributor.authorRecker, Robert R.en_US
dc.contributor.authorWatson, Patrice A.en_US
dc.contributor.authorLappe, Joan M.en_US
dc.date.accessioned2013-09-18T19:04:16Z
dc.date.available2013-09-18T19:04:16Z
dc.date.issued2004-08en_US
dc.identifier.otherNIAMS-115 (National Institute of Arthritis and Musculoskeletal and Skin Diseases)en_US
dc.identifier.otherIRB 01-12531 (Creighton University)en_US
dc.identifier.otherNCT00074711 (ClinicalTrials.gov)en_US
dc.identifier.urihttp://hdl.handle.net/10504/45928
dc.description.abstractThis data has been de-identified to protect the privacy of the research participants.en_US
dc.description.sponsorshipNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)en_US
dc.formatThis was originally an Access database. It was stripped of identifying information and converted into Excel spreadsheets.en_US
dc.formatA CSV (text) file was also created from the spreadsheeten_US
dc.format.extent10 KB xlsxen_US
dc.format.extent1 KB csven_US
dc.format.mimetypeapplication/vnd.openxmlformats-officedocument.spreadsheetml.sheet (.xlsx)en_US
dc.publisherCreighton Osteoporosis Research Centeren_US
dc.relationThis was originally an Access database. It was stripped of identifying information and converted into Excel spreadsheets.en_US
dc.subject.otherReports, Adverse Eventen_US
dc.titleTable 6 - Adverse Eventsen_US
dc.rights.holderHeaney, Robert P.en_US
dc.publisher.locationOmaha, NEen_US
dc.title.workBone Sparing by Calcium Salts With and Without Extra Phosphorusen_US
dc.description.noteDescription from ClinicalTrials.gov: Osteoporosis is the most common type of bone disease. Calcium supplements normally used in anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts bind phosphorus from food in the intestine and restrict phosphorus available for bone building. This study will evaluate the efficacy of adding calcium phosphate to a regimen of teriparatide and vitamin D in increasing bone mineral density in women with osteoporosis. It is hypothesized that the group taking the phosphate-containing calcium supplement will have greater gains in bone mineral density (BMD) during the course of the study than the group not receiving phosphate. All participants will receive teriparatide and vitamin D during the course of the 12-month study. Participants will be randomly assigned to one of two groups. One group will receive calcium phosphate and the other will receive calcium carbonate. BMD will be measured at spine and hip at baseline and at 3, 6, and 12 months of treatment.en_US
dc.program.unitSchool of Medicineen_US
dc.program.unitDepartment of Medicineen_US
dc.program.unitEndocrinologyen_US
dc.program.unitOsteoporosisen_US
dc.contributor.cuauthorHeaney, Robert P.en_US
dc.contributor.cuauthorRecker, Robert R.en_US
dc.contributor.cuauthorWatson, Patrice A.en_US
dc.contributor.cuauthorLappe, Joan M.en_US
dc.description.note22004-2008
dc.identifier.grantnoR01 AR048846 (National Institute of Health)en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record